Contact dermatitis (CD) is a common clinical condition affecting the skin. Most commonly it is caused by irritants and only a relatively small proportion is due to allergy. Allergic contact dermatitis (ACD) frequently involves the hands and face. During the acute phase the most common symptom is itching, which may be associated with vesicle and bullae formation. Scaling and lichenification are features of chronic ACD. As opposed to irritant contact dermatitis (ICD), ACD is believed to be an immunological reaction and requires prior allergen sensitization. However, there is evidence indicating that the immune system plays a significant role in the pathogenesis of ICD as well.

ICD is thought to be a non-antigen-specific inflammatory process mediated by haptens and associated with release of cytokines and recruitment of dendritic cells. Hapten-induced ICD is thought to evolve into ACD by acquisition of antigenic properties by haptens subsequent to their binding and modification of self-proteins. Recently it has been suggested that ICD and ACD are closely associated, and the induction of ICD may be a prerequisite for the development of ACD. ACD comprises about 6% to 10% of all dermatology clinic visits and is associated with significant morbidity. Allergen sensitization is believed to be dependent on the degree of exposure to the allergen and exhibits...
strong individual variation. Genetic predisposition appears to be an important factor, as some individuals are more easily sensitized to common allergens than others. In addition, regional and environmental factors may also influence the exposure patterns and could be responsible for the variations in the patterns of skin reactivity observed in different parts of the world.

The patch test is a useful tool for the detection and identification of contact allergens, despite the fact that 10% to 15% of normal healthy individuals may react to one or more allergens. In patients with ACD, detection of the relevant agent by patch testing is crucial for instituting appropriate prevention and treatment. Avoidance of the relevant allergen/s has recently been shown to be associated with significant improvement in over 85% of patients with ACD. Over 3000 chemicals are known to cause ACD but, fortunately, only a small number of these chemicals are responsible for symptoms in the majority of cases. Thorough knowledge of the common allergens and a comprehensive history of the patient’s exposure to possible allergens will be valuable for selecting the test panels for patch testing. This retrospective study examines patch test reactivity to common allergens in patients with clinical suspicion of CD over a period of 2 years.

PATIENTS AND METHODS
A total of 196 patients with the clinical diagnosis of CD were referred to the allergy clinic at KKU Hospital for patch testing between April 2008 and March 2010. Because of the lack of access to the patient records, clinical data could not be collected.

The patch test was performed using T.R.U.E. Test (Thin-layer Rapid Use Epicutaneous Test, Mekos Laboratories AS, Denmark) with a panel of 24 allergens/allergen mixes. The test panel was applied on the upper part of the patient’s back on healthy skin free of acne, scars, dermatitis, or any other skin condition that might interfere with the interpretation of the results. Patients were instructed to wear the patch for 48 hours without removing it and to avoid contact with water. Interpretation of the results was performed first after 48 hours and then again 72 to 96 hours after the application. This protocol allowed sufficient time for the allergic reactions to fully develop and for mild irritant reactions to disappear. Patients were instructed to report back to the clinic in case of delayed reactions. The interpretation of the results was performed in accordance with the recommendations of the International Contact Dermatitis Research Group (ICDRG) and the North American Contact Dermatitis Group (NACDG). Statistical analysis of the data was performed using MedCalc software version 11.5.1.0 for comparison of the proportions. P≤.05 was considered statistically significant.

RESULTS
Out of 196 patients suspected to have CD, 91 (46.4%) individuals tested positive to either one or more allergens; these included 24 males with a mean age of 34 (11.6) years and 67 females with a mean age of 37 (8.3) years. These 91 patients included 82 (91.1%) of Saudi nationality and 9 (8.9%) patients of other nationalities. Among the 91 patients, 56 (61.5%) reacted positively to a single allergen. A female preponderance was evident among the patients with CD, with 67 (73.6%) females compared to 24 (26.4%) males showing positive reaction to either one or more allergens in the patch test panel. Figure 1 shows the pattern of patch test reactivity among the patients with CD. Nickel sulfate was found to be the most frequently reacting allergen, with 33 (36.2%) patients showing reaction to the allergen. A positive reaction was seen with p-phenylenediamine in 14 patients (15.3%), with p-tert-butylphenolformaldehyde resin in 13 patients (14.2%), with thimerosal in 13 patients (14.2%), and with colophony in 9 patients (9.8%). Reactivity against the rest of the panel was not remarkable. Table 1 shows the gender differences among the patients with CD where notable numbers of patients reacted to patch test allergens. The group of 33 patients reacting positively to nickel sulfate had a significantly higher proportion of females (28/33; 84.8%) than males (5/33; 15.2%) (P=.0001). Although the difference was not as marked as with nickel sulfate, a significantly higher number of females than males reacted to p-tert-butylphenol-formaldehyde resin (P=.0001) and thimerosal (P=.03).

DISCUSSION
Nickel sulfate was found to be the most frequently (36.2%) reacting patch test allergen in this study. Similar findings were noted in an earlier study performed among adolescents between the ages of 10 to 19 years where 56% of patients reacted to one or more patch test allergens and among them 31% were found to be allergic to nickel. Path test reactivity between 13% and 17% has also been reported. The NACDG has consistently ranked nickel as the most frequently reacting allergen among positive patch test reactions. Because of the presence of nickel in a large variety of products it is very difficult to avoid contact with nickel and this is probably the main reason for the high incidence of nickel allergy. An increase in patch test reactivity to nickel among patients with CD has also been observed: two separate studies, one per-
formed from 1994 to 1996 and the other from 1998 to 2000, reported nickel reactivity in 14.3% and 16.2% of patients, respectively. Collectively, these data indicate that nickel sulfate is not only a common contact sensitizer but that allergy to nickel is gradually increasing, probably due to the increased exposure to nickel.

A significantly higher proportion of females with CD reacted to nickel in the present study. Women have already been reported to be at a higher risk of acquiring allergy to nickel (20.4% vs 5.8% in men). Differences in exposure have been postulated to be the cause for this disparity. Early skin contact with nickel in earrings or pins have been implicated in the increased skin reactivity to nickel among females. Attempts to decrease exposure to nickel by legal restriction on earrings with high nickel content have resulted in 64% reduction in nickel allergy among young girls. It has also recently been reported that nickel regulation in Denmark has not only decreased nickel allergy among young females, it has also reduced the occurrence of new cases. Since 2001, the European Parliament and European Council have also imposed restrictions on the use of objects containing nickel that may cause skin sensitization. Nickel allergy appears to be a major public health problem that requires serious consideration and implementation of policies directed towards reducing skin contact with nickel.

\(\textit{p}\)-Phenylenediamine (PPD) is commonly used in hair dyes and in Bandrowski base, a primer that forms quickly upon storage of PPD and is believed to be the main allergen in patients reacting to PPD. A sizeable proportion (15.3%) of patients with CD reacted to PPD in the present study, higher than the proportion (7%) reported in a recent study from Thailand. A significant increase in the skin reactivity to PPD has been observed and this alteration in PPD reactivity has been attributed to the changes in exposure patterns. The use of hair dyes is increasing and, consequently, so is the exposure to PPD, thus accounting for the substantially high prevalence of symptoms such as redness, scaling, itching, or edema following hair dye application. It is therefore imperative to introduce measures to curtail exposure to this sensitizer.

\(\textit{p}\)-tert-Butylphenol-formaldehyde resin is an alkylphenol resin made from \(\textit{p}\)-tert-butylphenol and formaldehyde. It is included in many adhesive formulations. Glues containing \(\textit{p}\)-tert-butylphenol-formaldehyde resin are used in leather products such as shoes, watchstraps, handbags, building materials, motorcars, and electrical products. Positive patch test reactions to \(\textit{p}\)-tert-butylphenol-formaldehyde resin were detected in 14.2% of the patients with CD in the present study, and reactivity was more frequently seen among females. This appears to be a significantly high percentage when compared to the previous reports that have documented reactivity to \(\textit{p}\)-tert-butylphenol-formaldehyde resin of 2.3% in 1984, 1.7% in 1996, and 2.2% in 2000.

Thimerosal patch test reactivity observed in the present study was 14.2%, which was also higher than the recently reported figures of 6.4% in adults and 1.7% in children. Thimerosal has for long been used as a preservative in medical preparations and vaccines.

Table 1. Gender differences among patients with contact dermatitis in cases of notable patch test allergen reactivity was observed.

| Allergen                          | Number of patients | Number of females (%) | Number of males (%) | \(P\)       |
|----------------------------------|--------------------|----------------------|---------------------|------------|
| Nickel                           | 33                 | 28 (84.8)            | 5 (15.2)            | .0001      |
| \(\textit{p}\)-Phenylenediamine  | 14                 | 6 (42.8)             | 8 (57.2)            | Not significant |
| \(\textit{p}\)-tert-Butylphenol formaldehyde resin | 13                  | 12 (92.3)            | 1 (7.7)             | .0001      |
| Thimerosal                       | 13                 | 10 (76.9)            | 3 (23.1)            | .03        |
| Colophony                        | 09                 | 7 (77.7)             | 2 (22.3)            | Not significant |

Figure 1. Pattern of allergen patch test reactivity among patients with contact dermatitis (n=91).
Its use in vaccines was abandoned in the United States due to public concern. Although the present study examined a relatively small number of patients with CD, comprised predominantly of Saudi nationality, it does however reveal a pattern of sensitization by contact allergens that this study population was exposed to. High reactivity to nickel has previously been reported from Saudi Arabia in 1995, though the pattern of allergen reactivity was different to what has been found in the present study. Large-scale studies are needed to further investigate the local allergens responsible for CD in Saudi Arabia, which will aid implementation of appropriate measures for avoidance of exposure.

**REFERENCES**

1. Züg KA, Warshaw EM, Fowler JF, Maibach HI, Belsito DL, Pratt MD, et al. Patch-test results of the North American Contact Dermatitis Group 2005-2006. Dermatitis 2009;20:149-60.
2. Mowad CM, Marks JG. Allergic contact dermatitis. In: Bologna JL, Jorizzo JL, Rapini RP, et al. editors. Dermatology. 2nd ed. Spain: Elsevier; 2008. p. 209-22.
3. Mark BJ, Slavin RG. Allergic contact dermatitis. Med Clin N Am 2006;90:169-85.
4. Levin CV, Maibach HI. Irritant contact dermatitis: Is there an immunologic component? Int Immunopharmacol 2002;2:183-9.
5. Baskettier DA, Gerberick GF, Kimber I, Willis C. Contact irritation mechanisms. In: Toxicology of contact dermatitis. West Sussex P019 1UD, England: John Wiley and Sons; 1999. p. 11-38.
6. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G. Chemokine networks in inflammatory skin diseases. Eur J Dermatol 2004;14:203-8.
7. Saint-Mezard P, Berard F, Dubois B, Kaiserlian D, Nicolas JF. The role of CD4+ and CD8+ T cells in contact hypersensitivity and allergic contact dermatitis. Eur J Dermatol 2000;14:131-6.
8. Lepoittevin J, Leblond I. Hapten-peptide T cell receptor interactions: Molecular basis for recognition of haptens by T lymphocytes. Eur J Dermatol 1997;7:151-4.
9. Bonneville M, Chavagnac C, Vocanson M, Rozieres A, Benetiére J, Pernet I, et al. Skin contact irritation conditions the development and severity of allergic contact dermatitis. J Invest Dermatol 2007;127:1430-7.
10. Sherezé PF. Controversies in contact dermatitis. Am J Contact Dermat 1994;4:130-5.
11. Rycroft RJ, Menne T, Frosch PJ, Lepoittevin JP, editors. Textbook of contact dermatitis. Berlin: Springer-Verlag; 2001. p. 439-68.
12. Johansen J, Menne T, Christophersen J, Kaaber K, Veien N. Changes in the pattern of sensitization to common contact allergens in Denmark between 1985-86 and 1997-98, with a special view to the effect of preventive strategies. Br J Dermatol 2000;142:490-5.
13. Schnuch A. PAFs: Population-adjusted frequency of sensitization. Contact Dermatitis 1996;34:377-82.
14. Sidenari S, Manzini BM, Danese P, Motosoleta A. Patch and prick test study of 593 healthy subjects. Contact Dermatitis 1998;20:162-7.
15. Nielsen NH, Menne T. Allergic contact sensitization in an unselected Danish population. The Glostrup Allergy Study, Denmark. Acta Derm Venereol 1992;72:456-60.
16. Rajagopal R, Anderson RT. Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis. Am J Contact Dermat 1997;8:215-21.
17. Gallo R, Baldari M, Faust V, Montinari M, Santero F, Cristiana K, et al. Measurement of a possible patch-testing outcome indicator. Contact Dermat 2010;62:195-9.
18. Allergic Contact Dermatitis: Patch Testing Beyond the T.R.U.E. TEST. J Clin Aesthet Dermatol. 2010;3:39-41.
19. Duarte I, Lazzarini R, Kobata CM. Contact dermatitis in adolescents. Am J Contact Dermat 2003;14:200-4.
20. Schläfer T, Böhler E, Ruhdorfer B, Weigl L, Wessner D, Filipiak B, et al. Epidemiology of contact allergy in adults. Allergy 2001;56:1192-6.
21. Uter W, Hegewald J, Aberer W, Ayala F, Bircher AJ, Brach J, et al. The European standard series in 9 European countries, 2002/2003 - first results of the European Surveillance System on Contact Al- lergies. Contact Dermatitis 2005;53:136-45.
22. Liden C. Nickel in jewelry and associated products. Contact Dermatitis 1992;26:74-5.
23. Marks JG, Belsito DV, DeLeo VA, Fowler JF Jr, Fransway AF, Maibach HI, et al. North American contact dermatitis group patch-test results, 1998–2000. Am J Contact Dermat 2003;14:59-62.
24. Modjehadi BS, Modjehadi SP, Maibach HI. The sex of the individual as a factor in allergic contact dermatitis. Contact Dermatitis 2004;50:53-9.
25. Jensen CS, Ustby S, Baadsgaard O, Valkun A, Menne T. Decrease in nickel sensitization in a Danish schoolgirl population with ears pierced after implementation of a nickel-exposure regulation. Br J Dermatol 2002;146:636-42.
26. Thyssen JP, Hald M, Avnortz C, Veien NK, Lauerberg G, Nielsen NH, et al. Characteristics of nickel-allergic dermatitis patients seen in private dermatology clinics in Denmark: A questionnaire study. Acta Derm Venereol. 2009;89:384-8.
27. European Parliament and Council Directive 94/27/EC of 30 June 1994 amending for the 12th time Directive 76/769/EEC on the approximation of the laws, regulations and administrative provisions of the Member States relating to restrictions on the marketing and use of certain dangerous substances and preparations. Official Journal EEC 1994:1-2.
28. Krasteva M, Nicolas JF, Chabeau G, Garrigue JL, Bour H, Thivolet, J, et al. Dissociation of allergenic and immunogenic functions in contact sensitisation to paraphenylenediamine. Int Arch Allergy Immunol 1992;102:203-4.
29. Dispanurut W. Contact allergy in eczema patients in Thammasat University Hospital. J Med Assoc Thai. 2010;93 Suppl:757-14.
30. Chew AL, Bashir SJ, Hawk JL, Palmer R, White JR, McFadden JP. Contact and photocontact sensitization in chronic actinic dermatitis: A changing picture. Contact Dermatitis. 2010;62:42-6.
31. The European Cosmetic Toiletry and Perfumery Association (Colipa). The European cosmetic, toiletry and perfumery Market 2003. 2004. p. 1-28.
32. Sosted H, Hesse U, Menne T, Andersen KE, Johansen JD. Contact dermatitis to hair dyes in an adult Danish population – an interview based study. Br J Dermatol 2005;153:132-5.
33. Hayakawa R, Suzuki M, Kaniwa M. A case of allergic contact dermatitis due to para-tert-ary butylphenol formaldehyde resin. Environ Dermatol 1994;1:171-17.
34. Adachi A. JSCD Research Group Study Result of Patch-test with standard allergen series of the Research Group of the Japanese patients with pigmented contact dermatitis of lichenoid type in 1993. Environ Dermatol 1996;2:140-50.
35. Kurikawa Y. Group study of the optimum concentration of ketoprofen, naprofen acid, suprofen and oxybenzone of the Japanese Standard Allergens and gold sodium thiosulfate in 2000. Environ Dermatol 2002;2:39-46.
36. Yao JY, Al Naami M, Markowitz Q, Hadi SM. Allergic contact dermatitis: Patch testing results at Mount Sinai Medical Center. Skimmed 2010;8:257-60.
37. Milengou M, Tagka A, Armenaka M, Kimpouri V, Kounimitzis D, Katsarou A. Patch test children: A review of 13 years of experience in comparison with previous data. Pediatr Dermatol 2010;27:255-9.
38. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001;107:1147-54.
39. el-Rab MO, al-Sheikh O. Is the European standard series suitable for patch testing in Riyadh, Saudi Arabia? Contact Dermatitis 1995;33:316-4.